Transurethral laser ablation of the prostate (TULAP) in high-risk patients. Perioperative morbidity and results after 6 months in 72 patients;Transurethrale Laserablation der Prostata (TULAP) bei Hochrisikopatienten mit obstruktiver BPH. Perioperative Morbiditat und 6-Monats-Ergebnisse bei 72 Patienten

Urologe - Ausgabe A

Volumn 36, Issue 2, 1997, Pages 165-172

  Miller, J ^a   Erkens, U ^a   Fischer, C ^a   Klotzer J P ^a   Weidner, W ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

benign prostatic hypertrophy; high risk patients; morbidity; obstruction; visual laser ablation of the prostate

Indexed keywords

ADULT; ARTICLE; BLADDER OBSTRUCTION; HIGH RISK PATIENT; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROSTATE HYPERTROPHY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ENDOSCOPES; FOLLOW-UP STUDIES; HUMANS; LASER SURGERY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RISK FACTORS; URINARY BLADDER NECK OBSTRUCTION; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 0030890205     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050084     Document Type: Article

References (31)

1. Almer FM, Altwein JE (1994) Transurethrale Prostataresektion: Steht ein Wandel in der Therapie der benignen Prostatahyperplasie bevor? Aktuel Urol 25: 143-153
2. Altwein JE (1992) International Workshop on Prostatic Cancer and Benign Hypertrophy: Eine Konsensus-Konferenz. Aktuel Urol 23: 131-135
3. Altwein JE, Almer F (1994) Is there a change in the treatment of benign prostatic hyperplasia? Urol Int 52: 1-3
4. Bolton DM, Costello AJ (1994) Management of benign prostatic hyperplasia by transurethral laser ablation in patients treated with Warfarin anticoagulation. J Urol 151: 79-81
5. Conrad S, Gonnermann D, Heinzer H, Kabalin JN, Huland H (1995) Transurethrale Lasertherapie der benignen Prostatahyperplasie. Urologe A 34: 25-34
6. Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J (1992) Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 69: 603-608
7. Costello AJ, Johnson DE, Bolton DM (1992) Nd: YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy. Lasers Surg Med 12: 121-124
8. De la Rosette JJMCH, Froeling FMJA, Alivizatos G, Debruyne FMJ (1994) Laser ablation of the prostate: experience with an ultrasound guided technique and a procedure under direct vision. Eur Urol 25: 19-24
9. Dixon CM, Lepor H (1992) Laser ablation of the prostate. Semin Urol 10: 273-277
10. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC (1992) Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 147:1566-1573
11. Ena J, Amador C, Martinez C, Ortiz de la Tabla V (1995) Risk factors for aquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 153: 117-120
12. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D (1988) Symptom status and quality of life following prostatectomy. JAMA 259: 3018-3022
13. Gottfried HW, Krautschik A, Hefty R, Weber HM, Frohneberg D, Hautmann RE (1995) Transurethrale Laserablation der Prostata (TULAP) - Erste Ergebnisse bei 188 Patienten. Urologe A 34: 132-137
14. Harzmann R, Weckermann D (1992) Bewertung neuer technischer Alternativverfahren zur Therapie der symptomatischen BPH. Urologe A 31: 150-158
15. Holtgrewe HL (1993) Guidance for clinical investigations of devices used for the treatment of benign prostatic hyperplasia. J Urol 150: 1588-1590
16. Holtgrewe HL (1994) Editorial: Benign prostatic hyperplasia. J Urol 152: 2030
17. Holtgrewe HL, Valk WL (1962) Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2015 cases. J Urol 87: 450-459
18. Johnson DE, Price RE, Cromeens DM (1992) Pathologic changes occuring in the prostate following transurethral laser prostatectomy. Lasers Surg Med 12: 254-263
19. Kabalin JN (1993) Laser prostatectomy performed with a right angle firing neodymium: YAG laser fiber at 40 watts pwoer setting. J Urol 150: 95-99
20. Kabalin JN, Bite G, Doll S (1996) Neodymium: YAG laser coagulation prostatectomy: 3 years of experience with 227 patients. J Urol 155: 181-185
21. Kabalin JN, Gill HS, Bite G, Wolfe V (1995) Comparative study of laser versus electrocautery prostatic resection: 18-month followup with complex urodynamic assessment. J Urol 153: 94-98
22. Lauven PM, Stoeckel H, Ebeling BJ (1990) Perioperative Morbidität und Mortalität geriatrischer Patienten - Eine retrospektive Studie an 3905 Fällen. Anästh Intensivther Notfallmed 25: 3-9
23. Malone PR, Cook A, Edmonson R, Gill MW, Shearer RJ (1988) Prostatectomy: patients' perception and long-term follow-up. Br J Urol 61: 234-238
24. Mangano DT, Böttiger BW (1995) Kardiovaskuläre Morbidität und Anästhesie. Anästhesiol Intensivmed Notfallmed Schmerztrier 30: 136-140
25. Mebust WK, Holtgrewe HL, Cockett ATK, Peters DC, Writing Committee (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 141: 243-247
26. Melchior J, Valk WL, Foret JD, Mebust WK (1974) Transurethral prostatectomy: computerized analysis of 2223 consecutive cases. J Urol 112: 634-642
27. Neal DE, Ramsden PD, Sharpies L et al (1989) Outcome of elective prostatectomy. Br Med J 299: 762-767
28. Morris JP, Morris DM, Lee RD, Rubenstein MA (1993) Visual laser ablation of the prostate: clinical experiences in 108 patients. J Urol 150: 1612-1614
29. Schulze H, Senge T (1992) BPH 1992. Einführung zum Thema. Urologe A 31: 127-128
30. Smith JA jr (1995) Commentary on the desired tissue effects for laser treatment of the prostate and how thea can best be achieved? J Urol 153: 2
31. Tanow J (1986) Der Herzinfarktpatient in der oeprativen Medizin. Anästh Intensivmed 27: 116-128